Please assess the completion status of the following clinical trial:

Trial Title: Precision Dosing of Infliximab Versus Conventional Dosing of Infliximab

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of CD or UC based on endoscopy and pathology~* 18 years or older~* Clinical remission, based on a Harvey Bradshaw Index (HBI) score ≤4 or a Partial Mayo (PM) score ≤2, for CD and UC~* Scheduled IFX maintenance treatment, regardless of interval/dosing~Exclusion Criteria:~- Dilatation or resectional surgery because of stenotic IBD in the past year

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- PRECISION dosing (Type: EXPERIMENTAL): Infliximab may vary between 1-10 mg/kg and the interval between 4 and 12 weeks.
- Conventional dosing of Infliximab (Type: NO_INTERVENTION): Infliximab 5 mg/kg every 8 or 6 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).